High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
749.14M
+20.42%
2.090
+15.48%
784.32M
+24.95%
2.348
+38.91%
736.52M
+28.63%
1.867
+166.69%
Estimates Revision
The market is revising Upward the revenue expectations for Neurocrine Biosciences, Inc. (NBIX) for FY2025, with the revenue forecasts being adjusted by 3.82% over the past three months. During the same period, the stock price has changed by 8.04%.
Revenue Estimates for FY2025
Revise Upward
+3.82%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+9.38%
In Past 3 Month
Stock Price
Go Up
+8.04%
In Past 3 Month
22 Analyst Rating
0Wall Street analysts forecast NBIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NBIX is 162.71 USD with a low forecast of 115.00 USD and a high forecast of 192.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Buy
2 Hold
0 Sell
Strong Buy
0Current: 125.010
Low
115.00
Averages
162.71
High
192.00
0Current: 125.010
Low
115.00
Averages
162.71
High
192.00
Guggenheim
Yatin Suneja
Buy
maintain
$165 -> $175
2025-08-01
Reason
Guggenheim
Yatin Suneja
Price Target
$165 -> $175
2025-08-01
maintain
Buy
Reason
Guggenheim analyst Yatin Suneja raised the firm's price target on Neurocrine to $175 from $165 and keeps a Buy rating on the shares. Non-GAAP EPS came in above the Street's forecast and the company narrowed FY25 Ingrezza sales guidance to $2.5-$2.55B, notes the analyst, who calls out the Phase 2 readout in MDD with NBI-770 and Phase 3 readouts in Dyskinetic Cerebral Palsy, both due in Q4, as the next key catalysts for Neurocrine.
Morgan Stanley
Overweight
maintain
$148 -> $150
2025-07-22
Reason
Morgan Stanley
Price Target
$148 -> $150
2025-07-22
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on Neurocrine to $150 from $148 and keeps an Overweight rating on the shares ahead of the company reporting Q2 results on July 30. The firm projects Q2 Ingrezza sales of $630M, aligning with consensus, and estimates Crenessity sales of $20M, slightly below the $23M consensus, the analyst noted. However, the firm continues to see "under-appreciated value in 2H and beyond," the analyst added in the firm's preview.
Truist
Danielle Brill
initiated
$163
2025-07-21
Reason
Truist
Danielle Brill
Price Target
$163
2025-07-21
initiated
Reason
Truist analyst Danielle Brill initiated coverage of Neurocrine with a Buy rating and $163 price target. Despite headwinds in the marketplace, the firm is "confident" in the outlook for the base Ingrezza business and views the Crenessity launch as the key growth driver over the next 12-plus months, the analyst tells investors. In addition, the remaining pipeline is "high-risk," but all potential upside to the firm's model, the analyst added.
Goldman Sachs
NULL -> Buy
initiated
$182
2025-07-10
Reason
Goldman Sachs
Price Target
$182
2025-07-10
initiated
NULL -> Buy
Reason
Goldman Sachs initiated coverage of Neurocrine with a Buy rating and $182 price target, implying 36% upside potential. The firm says Neurocrine has an attractive growth profile relative to its mid-cap peers, given the ongoing Crenessity launch. The company offers significant upside on positive clinical development over the next several years, the analyst tells investors in a research note.
UBS
Buy
maintain
$152 -> $174
2025-07-09
Reason
UBS
Price Target
$152 -> $174
2025-07-09
maintain
Buy
Reason
UBS raised the firm's price target on Neurocrine to $174 from $152 and keeps a Buy rating on the shares. UBS continues to see steady upside on the stock for remainder of 2025, and tells investors in a research note that for the stock to break from the recent range-bound action, consistently strong uptake on Crenessity is key. The stock is lot less polarized heading into the 2Q25 print, as opposed to 4Q24, UBS argues.
HC Wainwright & Co.
Andrew Fein
Strong Buy
Maintains
$185 → $168
2025-04-22
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$185 → $168
2025-04-22
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Neurocrine Biosciences Inc (NBIX.O) is 14.83, compared to its 5-year average forward P/E of 22.52. For a more detailed relative valuation and DCF analysis to assess Neurocrine Biosciences Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Undervalued
5Y Average PE
22.52
Current PE
14.83
Overvalued PE
27.86
Undervalued PE
17.18
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Fair
5Y Average EV/EBITDA
23.26
Current EV/EBITDA
16.71
Overvalued EV/EBITDA
31.05
Undervalued EV/EBITDA
15.47
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
6.02
Current PS
4.06
Overvalued PS
7.26
Undervalued PS
4.78
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 135.6% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 135.6% over the last month.
Sold
Bought
NBIX News & Events
Events Timeline
(ET)
2025-07-30
16:05:49
Neurocrine narrows FY25 Ingrezza net product sales view to $2.50B-$2.55B
2025-07-30
16:03:52
Neurocrine reports Q2 non-GAAP EPS $1.65, consensus $1.50
2025-07-14 (ET)
2025-07-14
08:34:59
Neurocrine presents one-year data from study of Crenessity
Sign Up For More Events
Sign Up For More Events
News
Preview
1.0
08-07PRnewswireNeurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
Preview
9.5
08-05NASDAQ.COMNeurocrine (NBIX) Q2 2025 Earnings Call Transcript
Preview
4.0
08-01NASDAQ.COMValidea Peter Lynch Strategy Daily Upgrade Report - 8/1/2025
Sign Up For More News
People Also Watch
FAQ
What is Neurocrine Biosciences Inc (NBIX) stock price today?
What is Neurocrine Biosciences Inc (NBIX)'s business?
What is the price predicton of NBIX Stock?
What is Neurocrine Biosciences Inc (NBIX)'s revenue for the last quarter?
What is Neurocrine Biosciences Inc (NBIX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Neurocrine Biosciences Inc (NBIX)'s fundamentals?
How many employees does Neurocrine Biosciences Inc (NBIX). have?